Literature DB >> 16954130

Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults.

C Yan1, S Zhao, S Jiang, Z Xu, L Huang, H Zheng, J Ling, C Wang, W Wu, H Hu, G Zhang, Z Ye, H Wang.   

Abstract

BACKGROUND: Surgical closure of patent ductus arteriosus (PDA) with severe pulmonary arterial hypertension in adults carries higher risk than in children.
OBJECTIVES: To investigate the application of self-expandable occluders for transcatheter closure of PDA associated with severe pulmonary arterial hypertension in adults, and the assessment of immediate and short-term results.
METHODS: 29 adult patients (6 men, 23 women) underwent attempted transcatheter closure of PDA at a mean (standard deviation (SD)) age of 31.1 (11.4) years (range 18-58 years) and a mean (SD) weight of 54.1 (7.1) kg (range 42-71 kg). On the basis of haemodynamic and clinical data obtained before and after trial occlusion, the final duct occlusion was determined and carried out. Radiographs of the chest, electrocardiograms and echocardiograms were used for follow-up evaluation of the treatment within 1 day, 1 month and 3-6 months after successful closure.
RESULTS: 20 of the 29 patients had successful occlusion (group 1), and 9 patients failed (named group 2). In group 1, in which occlusion was successful, mean (SD) pulmonary arterial pressures decreased markedly after trial occlusion: 78 (19.3) mm Hg (range 50-125 mm Hg) before occlusion and 41 (13.8) mm Hg (range 23-77 mm Hg) after occlusion. Systemic arterial oxygen saturation was found to be >90% in 19 patients and <90% in the remaining patient before inhalation of oxygen, and >95% during inhalation of oxygen or after occlusion in all 20 patients. In group 2, the occlusion was not successful, because in two patients the device was not available; another two patients showed worsening of symptoms. The other five patients showed increased pulmonary arterial pressures after trial closure; their mean (SD) pulmonary arterial pressures increased by 10.3 (6) mm Hg (4-16 mm Hg) after trial occlusion, and systemic arterial oxygen saturation was 85.5% (2.6%) (range 82.6-88%) before inhalation of oxygen and 94.7% (1.7%) (range 90.7-99.1%) during inhalation of oxygen. In group 1, the dimensions of the left atrium, left ventricle and pulmonary artery increased considerably in 3-6-months of follow-up compared with those of preocclusion.
CONCLUSIONS: Transcatheter closure is an effective treatment for adults with PDA associated with reversible severe pulmonary arterial hypertension. Further research is needed for the evaluation of long-term results.

Entities:  

Mesh:

Year:  2006        PMID: 16954130      PMCID: PMC1861497          DOI: 10.1136/hrt.2006.091215

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  12 in total

1.  Closure of the patent ductus arteriosus with the amplatzer PDA device: immediate results of the international clinical trial.

Authors:  H J Faella; Z M Hijazi
Journal:  Catheter Cardiovasc Interv       Date:  2000-09       Impact factor: 2.692

2.  Transcatheter closure of large patent ductus arteriosus (> or = 4 mm) with multiple Gianturco coils: immediate and mid-term results.

Authors:  Z M Hijazi; R L Geggel
Journal:  Heart       Date:  1996-12       Impact factor: 5.994

3.  Transcatheter closure of high pulmonary artery pressure persistent ductus arteriosus with the Amplatzer muscular ventricular septal defect occluder.

Authors:  B D Thanopoulos; G S Tsaousis; M Djukic; F Al Hakim; N G Eleftherakis; S D Simeunovic
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

4.  Further experience with transcatheter closure of the patent ductus arteriosus using the Amplatzer duct occluder.

Authors:  B D Thanopoulos; F A Hakim; A Hiari; Y Goussous; E Basta; A A Zarayelyan; G S Tsaousis
Journal:  J Am Coll Cardiol       Date:  2000-03-15       Impact factor: 24.094

5.  Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusion.

Authors:  A Krichenko; L N Benson; P Burrows; C A Möes; P McLaughlin; R M Freedom
Journal:  Am J Cardiol       Date:  1989-04-01       Impact factor: 2.778

6.  Results of anterograde transcatheter closure of patent ductus arteriosus using single or multiple Gianturco coils.

Authors:  Z M Hijazi; R L Geggel
Journal:  Am J Cardiol       Date:  1994-11-01       Impact factor: 2.778

7.  Transcatheter occlusion of the arterial duct with Cook detachable coils: early experience.

Authors:  O Uzun; S Hancock; J M Parsons; D F Dickinson; J L Gibbs
Journal:  Heart       Date:  1996-09       Impact factor: 5.994

8.  Transcatheter occlusion of the persistently patent ductus arteriosus. Forty-month follow-up and prevalence of residual shunting.

Authors:  M C Hosking; L N Benson; N Musewe; J D Dyck; R M Freedom
Journal:  Circulation       Date:  1991-12       Impact factor: 29.690

9.  Results of transcatheter closure of the patent ductus arteriosus with the Botallooccluder.

Authors:  V E Verin; S V Saveliev; S M Kolody; V I Prokubovski
Journal:  J Am Coll Cardiol       Date:  1993-11-01       Impact factor: 24.094

10.  Nonsurgical closure of patent ductus arteriosus: clinical application of the Rashkind PDA Occluder System.

Authors:  W J Rashkind; C E Mullins; W E Hellenbrand; M A Tait
Journal:  Circulation       Date:  1987-03       Impact factor: 29.690

View more
  24 in total

1.  Closure of a large patent ductus arteriosus in adults: first do no harm.

Authors:  Michael L Rigby
Journal:  Heart       Date:  2007-04       Impact factor: 5.994

2.  Patent ductus arteriosus in adults: Case report and review illustrating the spectrum of the disease.

Authors:  S A Wiyono; M Witsenburg; P P T de Jaegere; J W Roos-Hesselink
Journal:  Neth Heart J       Date:  2008-08       Impact factor: 2.380

3.  Transcatheter closure of patent ductus arteriosus in infantile form of Scimitar syndrome with a type II Amplatzer Ductal Occluder.

Authors:  Omar R J Tamimi; Mohammed Al-Ghaihab; Ali A Al Akhfash
Journal:  J Saudi Heart Assoc       Date:  2010-02-24

4.  Safety and efficacy of transcatheter closure of large patent ductus arteriosus in adults with a self-expandable occluder.

Authors:  Man-Li Yu; Xin-Miao Huang; Jia-Feng Wang; Yong-Wen Qin; Xian-Xian Zhao; Xing Zheng
Journal:  Heart Vessels       Date:  2009-11-22       Impact factor: 2.037

5.  The short- and medium-term results of transcatheter closure of atrial septal defect with severe pulmonary arterial hypertension.

Authors:  Zhi-wei Huang; Zhi-xin Fan; Jian-tao Sun; Wei-min Li; Yan-qing Gao; Yi-hua Quan; Ya-ming Geng; Yan-yan Niu; Bing-xiang Wu
Journal:  Heart Vessels       Date:  2011-09-17       Impact factor: 2.037

6.  Transesophageal echocardiography guided patent ductus arteriosus occlusion in adults with severe pulmonary hypertension through a parasternal approach.

Authors:  Xiao-Fu Dai; Liang-Wan Chen; Dong-Zhong Chen; Qiang Chen; Guo-Zhong Zhen; Gui-Can Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

7.  Association of aortic stiffness to brain natriuretic peptide in children before and after device closure of patent ductus arteriosus.

Authors:  Ragab A Mahfouz; Ahmad Alzaiat; Marwa Gad
Journal:  J Saudi Heart Assoc       Date:  2014-06-21

8.  Safety and Outcomes of Transcatheter Closure of Patent Ductus Arteriosus in Children With Pulmonary Artery Hypertension.

Authors:  Arash Salavitabar; Usha S Krishnan; Mariel E Turner; Julie A Vincent; Alejandro J Torres; Matthew A Crystal
Journal:  Tex Heart Inst J       Date:  2020-08-01

9.  Transcatheter closure of patent ductus arteriosus: Evaluating the effect of the learning curve on the outcome.

Authors:  Ahmad S Azhar; Ayman A Abd El-Azim; Hamed S Habib
Journal:  Ann Pediatr Cardiol       Date:  2009-01

10.  Transcatheter closure of large patent ductus arteriosus with severe pulmonary arterial hypertension: Short and intermediate term results.

Authors:  Parag S Bhalgat; Robin Pinto; Bharat V Dalvi
Journal:  Ann Pediatr Cardiol       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.